We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cytokinetics Announces Changes to Its Board of Directors

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cytokinetics Announces Changes to Its Board of Directors "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
"Since joining our Board over seven years ago, Michael has consistently made impactful contributions to Cytokinetics and has provided expert guidance to our company, especially in the areas of fiscal discipline and strategic corporate development," stated Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "On behalf of my fellow Board members and Cytokinetics' management team, I would like to thank Michael for his dedicated service to the company."

Mr. Santo "Sandy" Costa joins Cytokinetics' Board of Directors with more than 35 years of experience in the pharmaceutical and related industries, in which he has held numerous senior executive roles. Since 2007, Mr. Costa has served as Of Counsel to the law firm of Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan, L.L.P. of Raleigh, North Carolina specializing in corporate law for healthcare companies. From 1994 to 2002, Mr. Costa held various positions at Quintiles Transnational Corporation, most recently as Vice Chairman and before that as President and Chief Operating Officer, where he was deeply involved in managing the strategic growth of the company. Prior to joining Quintiles, Mr. Costa spent 23 years in the pharmaceutical industry, most recently as General Counsel and Senior Vice President, Administration with Glaxo Inc. Prior to joining Glaxo, Mr. Costa served as US Area Counsel with Merrell Dow Pharmaceuticals and as Food & Drug Counsel with Norwich Eaton Pharmaceuticals. Mr. Costa currently serves as Chairman of LaboPharm, Inc. He has served as Chairman of NeuroMedix and as a Director of CV Therapeutics, OSI Pharmaceuticals, NPS Pharmaceuticals, as well as other public and private companies. Mr. Costa is an Adjunct Professor in the clinical research program at the Campbell University School of Pharmacy and sits on the Board of Advisors of the Duke Cancer Patient Support Program Advisory Board, the Duke University Medical Center Board of Visitors, and the Duke Brain Tumor Advisory Board. Mr. Costa earned both a B.S. in Pharmacy and a J.D. from St. John's University.

"We are pleased to welcome Sandy to the Cytokinetics Board of Directors at a very important time in the maturation of our company, as we advance our pipeline of novel mechanism drug candidates towards late-stage development," continued Mr. Blum. "In addition to his operational leadership experience in the pharmaceutical and clinical services industries, Sandy is also well-versed in key legal and related governance and policy issues that are expected to influence important business dynamics in companies such as ours. We are looking forward to his insightful contributions to our Board."